At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 285 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen
In Brief
A Phase 2 clinical trial evaluating Placebo, lorundrostat Dose 1, and 1 other intervention for Hypertension. Completed, enrolled 285 participants across 104 sites.
Detailed Summary
A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartMar 2023
First PostedMar 2023
Primary CompletionJan 2025
TodayJul 2026
First PostedMar 15, 2023
Enrollment StartMar 13, 2023
Primary CompletionJan 15, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.3 years ago
Interventions
Placebodrug
Placebo once daily for 12 weeks
lorundrostat Dose 1drug
lorundrostat Dose 1 once daily for 12 weeks
lorundrostat Dose 2drug
lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria